Omega Therapeutics presents new preclinical data on OTX-2101

Omega Therapeutics announced new preclinical data supporting the potential of OTX-2101, a c-MYC-targeting epigenomic controller, MYC-EC, being developed for the treatment of non-small cell lung cancer, NSCLC, in combination with immune checkpoint inhibitors or EGFR inhibitors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which took place in Boston, Mass., October 11 – 15, 2023. Key Findings: Analysis of biopsy data from NSCLC patients treated with anti-PD1 or EGFR inhibitors found that high MYC mRNA levels correlated with a shorter time to disease progression, establishing a rationale to evaluate MYC-targeting epigenomic controllers in a combination treatment setting. Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity. Treatment with a MYC-EC plus an anti-PD-L1 antibody resulted in enhanced anti-tumor activity in a syngeneic mouse model of NSCLC. Combination of MYC-EC with EGFR inhibitor, osimertinib, synergistically reduced tumor cell viability in vitro and significantly inhibited tumor growth in vivo in a human xenograft model of NSCLC.